When to Combine Endocrine Therapy With a New Agent for Hormone Receptor-Positive Metastatic Breast Cancer in Postmenopausal Women

被引：0
|
作者：
Seidman, Andrew D. [1 ,2 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Weill Cornell Med Coll, New York, NY USA
来源：
ONCOLOGY-NEW YORK | 2016年 / 30卷 / 03期
关键词：
MONOTHERAPY; PALBOCICLIB;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：224 / 228
页数：5
相关论文
共 50 条
  • [31] Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline
    Rugo, Hope S.
    Rumble, R. Bryan
    Macrae, Erin
    Barton, Debra L.
    Connolly, Hannah Klein
    Dickler, Maura N.
    Fallowfield, Lesley
    Fowble, Barbara
    Ingle, James N.
    Jahanzeb, Mohammad
    Johnston, Stephen R. D.
    Korde, Larissa A.
    Khatcheressian, James L.
    Mehta, Rita S.
    Muss, Hyman B.
    Burstein, Harold J.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (25) : 3069 - +
  • [32] Lapatinib in Postmenopausal Women with Hormone Receptor-Positive, HER2-Positive Metastatic Breast Cancer Profile Report
    Curran, Monique P.
    BIODRUGS, 2011, 25 (01) : 53 - 54
  • [33] Endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: extending endocrine sensitivity
    Frassoldati, Antonio
    Biganzoli, Laura
    Bordonaro, Roberto
    Cinieri, Saverio
    Conte, Pierfranco
    De Laurentis, Michelino
    Del Mastro, Lucia
    Gori, Stefania
    Lauria, Rossella
    Marchetti, Paolo
    Michelotti, Andrea
    Montemurro, Filippo
    Naso, Giuseppe
    Pronzato, Paolo
    Puglisi, Fabio
    Tondini, Carlo Alberto
    FUTURE ONCOLOGY, 2020, 16 (05) : 129 - 145
  • [34] Adjuvant treatment in hormone receptor-positive early breast cancer: New approaches of endocrine therapy
    Nardin, Simone
    Ruelle, Tommaso
    Giannubilo, Irene
    Del Mastro, Lucia
    TUMORI JOURNAL, 2024, 110 (03): : 162 - 167
  • [35] Adjuvant Systemic Therapy for Postmenopausal, Hormone Receptor-Positive Early Breast Cancer
    Johnston, Stephen R. D.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2023, 37 (01) : 89 - 102
  • [36] Winpro: A window of opportunity study of endocrine therapy with and without prometrium in postmenopausal women with early stage hormone receptor-positive breast cancer
    Lau, Brandon
    Segara, Davendra
    Ong, Andrew
    Bingham, Janne
    Kiely, Belinda
    Carson, Emma-Kate
    Chen, Julia
    Mak, Cindy
    Warrier, Sanjay
    Hui, Mun
    Middleton, Kate
    Parker, Andrew
    Mann, Bruce
    Lindeman, Geoffrey
    Tilley, Wayne
    Lim, Elgene
    CANCER RESEARCH, 2021, 81 (04)
  • [37] Extended Adjuvant Endocrine Therapy in Hormone Receptor-Positive Early Breast Cancer
    Bracken-Clarke, Dara B.
    Lucas, Mairi W.
    Higgins, Michaela J.
    BREAST CARE, 2017, 12 (03) : 138 - 144
  • [38] Inflammatory response to neoadjuvant endocrine therapy in hormone receptor-positive breast cancer
    Oner, G.
    Van Berckelaer, C.
    Praet, M.
    Canturk, N. Z.
    Altintas, S.
    Tjalma, W.
    Berneman, Z.
    Peeters, M.
    Pauwels, P.
    van Dam, P. A.
    EUROPEAN JOURNAL OF CANCER, 2024, 200 : 79 - 80
  • [39] Efficacy of chemotherapy after hormone therapy for hormone receptor-positive metastatic breast cancer
    Mori, Ryutaro
    Nagao, Yasuko
    SAGE OPEN MEDICINE, 2014, 2
  • [40] Fulvestrant - A review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy
    McKeage, K
    Curran, MP
    Plosker, GL
    DRUGS, 2004, 64 (06) : 633 - 648
12345